Axel F. Sigurðsson

Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial

Paul M. Ridker, Jean MacFadyen, Tom Thurén et al. · The Lancet · 2017 · 1.3K citations · Full text

Inflammation, Allergy, Lung Inflammation +11

Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

Paul M. Ridker, Jean MacFadyen, Peter Libby et al. · The Lancet · 2017 · 847 citations · Full text

Cardiovascular Toxicity, C-reactive Protein Reduction, Cardiovascular Disease +8

Effects of a 5-Lipoxygenase–Activating Protein Inhibitor on Biomarkers Associated With Risk of Myocardial Infarction

Håkon Håkonarson, Sverrir Thorvaldsson, Anna Helgadóttir et al. · JAMA · 2005 · 233 citations

The Effect of Physical Training in Chronic Heart Failure

Sólrún Jónsdóttir, Karl Andersen, Axel F. Sigurðsson et al. · European Journal of Heart Failure · 2005 · 165 citations

Short- and long-term neurohormonal activation following acute myocardial infarction

Axel F. Sigurðsson, Peter Held, Karl Swedberg · American Heart Journal · 1993 · 133 citations

Cardiovascular Disease, Neurophysiology, Medicine +7